<DOC>
	<DOCNO>NCT02301117</DOCNO>
	<brief_summary>Study evaluate safety , tolerability , pharmacokinetics TAS-102 patient advance solid tumor vary degree renal impairment .</brief_summary>
	<brief_title>A Phase I Study TAS-102 Patients With Advanced Solid Tumors With Renal Impairment</brief_title>
	<detailed_description>This Phase 1 , open-label study evaluate safety , tolerability , pharmacokinetics TAS-102 patient advance solid tumor vary degree renal impairment . The study conduct 2 part : Pharmacokinetic Part ( Cycle 1 ) Extension Part ( Cycles 2 beyond ) . Patients may continue receive treatment TAS-102 study extension part completion Pharmacokinetic Part .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Inclusion 1 . Has provide write informed consent 2 . Has advance solid tumor ( exclude breast cancer ) 3 . Has normal renal function , mild , moderate , severe renal impairment dialysis 4 . ECOG performance status â‰¤2 5 . Is able take medication orally 6 . Has adequate organ function 7 . Women childbearing potential must negative pregnancy test must agree adequate birth control conception possible . Males must agree adequate birth control . Exclusion 1 . Certain serious illness medical condition ( ) 2 . Has certain recent treatment e.g . major surgery , anticancer therapy , extend field radiation , receive investigational agent , within specified time frame prior study drug administration 3 . Has receive TAS102 4 . Has unresolved toxicity great equal CTCAE Grade 2 attribute prior therapy 5 . Is pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Renal</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Renal Impairment</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Advance Solid Tumor</keyword>
	<keyword>Creatinine Clearance</keyword>
	<keyword>Kidney Neoplasms</keyword>
	<keyword>Renal Tumor</keyword>
	<keyword>Kidney</keyword>
	<keyword>Urology</keyword>
	<keyword>Pharmacologic Action</keyword>
</DOC>